{
    "clinical_study": {
        "@rank": "43689", 
        "arm_group": [
            {
                "arm_group_label": "pimecrolimus 10 mg/g cream", 
                "arm_group_type": "Experimental", 
                "description": "Active drug"
            }, 
            {
                "arm_group_label": "Vehicle cream", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo drug"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to validate a left-right design with respect to detecting a\n      difference in efficacy after 3 weeks of treatment between an active treatment and a vehicle\n      in adults with mild to moderate atopic dermatitis"
        }, 
        "brief_title": "A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Male and female subjects, 18 years or older\n\n          -  2. Subject with atopic dermatitis with mild to moderate disease severity\n\n          -  3. Two symmetrical and comparable atopic dermatitis treatment areas\n\n          -  4. Female volunteers of childbearing potential must either be surgically sterile or\n             agree to use a reliable method of contraception\n\n        Exclusion Criteria:\n\n          -  1. Any condition in the target areas that in the opinion of the investigator could\n             interfere with clinical assessments, e.g. acne, infection, rash other than atopic\n             dermatitis, sunburn, hyper- or hypopigmentation, scars\n\n          -  2. Dark-skinned persons whose skin colour prevents reliable clinical assessments\n\n          -  3. Any permanent (or transient within 28 days prior to dosing) disease that may\n             interfere with the subjects safe participation in the trial, with the subjects\n             ability to participate in the trial or with the clinical assessments\n\n          -  4. Pregnancy or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103725", 
            "org_study_id": "EXP-1092"
        }, 
        "intervention": [
            {
                "arm_group_label": "pimecrolimus 10 mg/g cream", 
                "intervention_name": "pimecrolimus 10 mg/g cream", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle cream", 
                "intervention_name": "Vehicle cream", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pimecrolimus", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "last_name": "Heinrich Siemetzki, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Hamburg", 
                    "country": "Germany", 
                    "zip": "20095"
                }, 
                "name": "bioskin GmbH"
            }, 
            "investigator": {
                "last_name": "Heinrich Siemetzki, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Multi-Centre, Randomised, Vehicle-Controlled, Double-Blinded, Explorative Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis Over a Treatment Period of Three Weeks", 
        "overall_contact": {
            "email": "rikke.fischer@leo-pharma.com", 
            "last_name": "Rikke L Fischer", 
            "phone": "+4544945888"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of the treatment effect defined as total sign score on the treated area at end of the 3 weeks treatment period", 
            "safety_issue": "No", 
            "time_frame": "3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103725"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of adverse events during the 3 weeks treatment period", 
            "safety_issue": "Yes", 
            "time_frame": "3 weeks"
        }, 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}